Posted by Michael Wonder on 10 Jul 2019
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
9 July 2019 - A unit of Novartis said on Tuesday it would make partner Adamis Pharmaceuticals Corp’s emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan’s rival product, EpiPen.
The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner.
Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.
